Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021, with a specific reporting date of October 12, 2021. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively reports on specific share transactions executed on October 7, 2021, on the London Stock Exchange (XLON).
| Transaction Type | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (25p each) | £13.9464 | 1,843 shares |
Note: The total volume of 1,843 shares is the aggregate of individual transactions reported for Ms. S. Jackson (1 share), Mr. D. Jackson (1 share), Ms. V. Whyte (34 shares), Mr. I. Whyte (1,244 shares), and Ms. D. Connor (563 shares).
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents compliance with disclosure requirements for insider share acquisitions resulting from dividend re-investment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were routine acquisitions of ordinary shares following the re-investment of dividends paid to shareholders on October 7, 2021.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved senior executives (SVP, Company Secretary, President) and their closely associated persons.
- Share Price: The execution price for all transactions was £13.9464 per share.
- Financial Data: This document does not provide GSK's quarterly or annual financial performance; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit data.